Exfoliated dermatitis and hepatitis to first line Anti-Tubercular Therapy with treatment of Drug-Sensitive Tuberculosis with second line Anti-Tubercular Therapy: a roller coaster ride

S. Spalgais, Ahmed Safwan M., P. Mrigpuri, Raj Kumar
{"title":"Exfoliated dermatitis and hepatitis to first line Anti-Tubercular Therapy with treatment of Drug-Sensitive Tuberculosis with second line Anti-Tubercular Therapy: a roller coaster ride","authors":"S. Spalgais, Ahmed Safwan M., P. Mrigpuri, Raj Kumar","doi":"10.4081/cdr.12.12626","DOIUrl":null,"url":null,"abstract":"The Adverse Drug Reactions (ADRSs) to Anti-Tubercular Therapy (ATT) have been reported from 8% to 85% worldwide, while the prevalence of ADRSs to 1st line ATT from India reported 2.3% to 17%, with more during the intensive phase and daily regime. However, cutaneous ADRSs related to ATT are less commonly seen. Common cutaneous ADRSs are maculopapular rash, urticarial, erythema multiforme, exfoliative dermatitis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Among the 1st line ATT, pyrazinamide is the most common cause at 2.38%, and isoniazid is reported the least at 0.98%. Exfoliated dermatitis is rarely seen with 1st line ATT therapy limited to some case reports and case series.","PeriodicalId":500149,"journal":{"name":"Chest disease reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest disease reports","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.4081/cdr.12.12626","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The Adverse Drug Reactions (ADRSs) to Anti-Tubercular Therapy (ATT) have been reported from 8% to 85% worldwide, while the prevalence of ADRSs to 1st line ATT from India reported 2.3% to 17%, with more during the intensive phase and daily regime. However, cutaneous ADRSs related to ATT are less commonly seen. Common cutaneous ADRSs are maculopapular rash, urticarial, erythema multiforme, exfoliative dermatitis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Among the 1st line ATT, pyrazinamide is the most common cause at 2.38%, and isoniazid is reported the least at 0.98%. Exfoliated dermatitis is rarely seen with 1st line ATT therapy limited to some case reports and case series.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用一线抗结核疗法治疗剥脱性皮炎和肝炎,用二线抗结核疗法治疗对药物敏感的结核病:过山车之旅
据报道,全球抗结核疗法(ATT)的药物不良反应(ADRSs)发生率为 8%至 85%,而印度报道的一线 ATT 药物不良反应发生率为 2.3%至 17%,其中强化阶段和每日治疗期间的发生率更高。然而,与 ATT 相关的皮肤 ADRS 并不常见。常见的皮肤 ADRS 包括斑丘疹、荨麻疹、多形性红斑、剥脱性皮炎和伴有嗜酸性粒细胞增多和全身症状的药物反应(DRESS)。在一线抗逆转录病毒药物中,吡嗪酰胺是最常见的致病原因,占 2.38%,异烟肼最少,占 0.98%。剥脱性皮炎在一线 ATT 治疗中很少见,仅限于一些病例报告和病例系列。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Tracheal stent migration in malignant central airway obstruction – a case report and systematic review of literature Association of Obstructive Sleep Apnea with co-morbidities in smokers versus non-smokers - an observational study Emerging immunological challenges in post-COVID individuals: insights from a case series and review The holy fluke - an unusual scenario of lung paragonimiasis Exfoliated dermatitis and hepatitis to first line Anti-Tubercular Therapy with treatment of Drug-Sensitive Tuberculosis with second line Anti-Tubercular Therapy: a roller coaster ride
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1